Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · March 14, 2022

Survival and Costs in Metastatic Melanoma in the Era of Novel Targeted and Immunotherapeutic Drugs

ESMO Open

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Viola Franke MD

ESMO Open
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
ESMO Open 2021 Dec 01;6(6)100320, MG Franken, B Leeneman, MJB Aarts, ACJ van Akkooi, FWPJ van den Berkmortel, MJ Boers-Sonderen, AJM van den Eertwegh, JWB de Groot, GAP Hospers, E Kapiteijn, D Piersma, RS van Rijn, KPM Suijkerbuijk, AAM van der Veldt, HM Westgeest, MWJM Wouters, JBAG Haanen, CA Uyl-de Groot

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated